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Objective: The optimal role for bare metal stents (BMS) or stent grafts (SG) in femoropopliteal occlusive disease (FPOD)
is as of yet undeﬁned. Understanding the clinical consequences of failure can help guide initial treatment decisions. The
goal of this study was to deﬁne the nature, frequency, and risk factors for adverse clinical events related to BMS and SG
failure in FPOD.
Methods: This is a single-institution retrospective review of primary endovascular interventions for FPOD using either
a BMS or SG, from September 2007 through October 2011. Patients were excluded if they had any previous lower
extremity interventions. Patient demographics, indications for intervention, anatomic characteristics, procedural details,
clinical outcomes, and reintervention details were reviewed. Clinical outcomes included the composite end point of any
reintervention, amputation, or stenosis, acute limb ischemia (ALI), and the composite end point of major adverse limb
events, which included a need for bypass, thrombolysis, or major amputation.
Results: Seventy-one limbs were treated with BMS and 63 with SG. Although patient demographics were largely similar
between cohorts, key differences included indication for intervention (percent claudication BMS vs SG, 34/71 (48%) vs
42/63 (67%); P < .05) and the TransAtlantic Inter-Society Consensus II classiﬁcation of lesions in the claudicant
subgroup (TransAtlantic Inter-Society Consensus D BMS vs SG, 4/34 (12%) vs 17/42 (40%); P < .01). Freedom from
reintervention at 1 year was better in the SG group (75% vs 64%; hazard ratio, 0.46; 95% conﬁdence interval, 0.25-0.78;
P < .01). Freedom from major adverse limb events was not different between groups; however, SG thrombosis resulted in
a more frequent need for thrombolysis. On multivariate analysis, treating with a BMS vs SG was a signiﬁcant predictor for
freedom from thrombolysis (hazard ratio, 0.53; conﬁdence interval, 0.37-0.76; P < .01). ALI during follow-up was seen
only in the SG group (nine vs zero events, log- rank; P < .02).
Conclusions: Failure modes of BMS and SG used to treat FPOD differ, and the clinical consequences may not be benign.
Claudicants may not revert back to claudication with treatment failure. Although the overall reintervention rate at 1 year
is lower for SG compared to BMS, we observed a higher rate of ALI and need for thrombolysis with SG failure. In light of
these differential risks of treatment failure, we believe that the use of SG as initial therapy for FPOD should be carefully
deliberated and mandates close postoperative surveillance. (J Vasc Surg 2013;58:1525-32.)Peripheral arterial disease is abundantly prevalent,
affectingup to20%of patients over the ageof 70.1The clinical
presentation is heterogeneous, ranging from asymptomatic
patients with abnormal ankle brachial indexes (ABIs) to
those with critical limb ischemia (CLI). In treating patients
with femoropopliteal occlusive disease (FPOD), the decision
to perform a revascularization procedure is dependent on
the presenting symptoms, degree of ischemia, patient-speciﬁc
factors that inﬂuence life expectancy or anesthetic risk, andthe Division of Vascular and Endovascular Surgery, University of
alifornia, San Francisco, San Franciscoa; and the Colorado Permanente
edical Group, Denver.b
or conﬂict of interest: none.
ented at the Twenty-seventh Annual Meeting of the Western Vascular
ciety, Park City, Utah, September 24, 2012.
rint requests: Shant M. Vartanian, MD, Division of Vascular and Endo-
scular Surgery, University of California, San Francisco, 400 Parnassus
ve A-581, Box 0222, San Francisco, CA 94143-0222 (e-mail: shant.
rtanian@ucsfmedctr.org).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.05.094disease-speciﬁc factors such as lesion characteristics, arterial
anatomy, and conduit availability.
Anatomically, the femoropopliteal segment is the most
commonly treated infrainguinal artery. Nationally, the
frequency of percutaneous revascularization techniques has
increased threefold over the last decade.2 In comparison to
bypass surgery, the popularity of percutaneous methods
is directly related to less patient discomfort, quicker
recovery, high technical success rates, and low periprocedural
morbidity.3Despite these advantages, there is a frequent need
for reinterventionandan incompleteunderstandingof the risk
factors for and the clinical consequences of midterm or late
treatment failure.
Both self-expanding nitinol stents (bare metal stents
[BMS]) and stent grafts (SG) have been shown to be viable
percutaneous treatment options for FPOD. Numerous
single-arm series, registry data, or trials comparing each type
of stent to bypass grafts individually have been reported.4-9
To date, comparative effectiveness studies directly comparing
the two have not yet been published, however, several
prospective trials are nearing completion.10 To garner the
maximum beneﬁt and cost-effectiveness of percutaneous
interventions, practitioners must include a thoughtful
approach to patient selection, including consideration of the1525
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ment failure. The purpose of this study was to compare the
nature and severity of late adverse events and the risk factors
for developing those events in patients treated with either
self-expanding nitinol stents or with SG in FPOD.METHODS
This is a retrospective review of two cohorts of con-
secutive patients with FPOD, treated with either self-
expanding nitinol stents or self-expanding SG at a single
tertiary care institution from October 2007 through
December 2011. Patients with previous infrainguinal inter-
ventions, either endovascular or open, were excluded
from the analysis. Patients with previous inﬂow pro-
cedures, including aortofemoral bypasses, iliac stents, or
femoral endarterectomies, and those with previous below-
the-ankle amputations were included in the analysis. Patients
without at least one follow-up visit postdischarge were
excluded.
With the approval of the University of California, San
Francisco Institutional Review Board, electronic medical
records were used to compile patient demographics, comor-
bid conditions, medication use, indication for intervention,
noninvasive vascular laboratory data, and degree of ischemia
classiﬁed by the Rutherford classiﬁcation system.11 The deci-
sion to implant a BMS or an SG was at the discretion of the
operating vascular surgeon. In most cases, the superﬁcial
femoral artery (SFA) was accessed percutaneously via
a contralateral retrograde approach. In 22 limbs, a ﬂush
SFA occlusion with concomitant common femoral disease
was treated with a hybrid femoral endarterectomy and SFA
endoluminal treatment. The preintervention angiogram
was used to classify atherosclerotic lesions according to the
TransAtlantic Inter-Society Consensus (TASC) II classiﬁca-
tion system.12Chronic total occlusions (CTOs)werenoted if
they were present of any length.Highly calciﬁed lesions were
deﬁned as those that are visible on ﬂuoroscopy without the
presence of contrast. Implant logs were used to capture the
model, diameter, length, and number of stents implanted.
Only heparin-bonded Viabahn (W. L. Gore, Flagstaff,
Ariz) SG were used in the SG cohort. The BMS cohort was
made up of a combination of Zilver (Cook Medical, Bloo-
mington, Ind), Everﬂex (eV3 Endovascular, Plymouth,
Minn), Protégé Everﬂex (eV3 Endovascular), Conformexx
(BardMedical, Covington,Ga), and SMART stents (Cordis,
Bridgewater, NJ). The completion angiogram was used to
capture the location of the stent within the SFA or popliteal
artery, and a runoff score using the four-level Society for
Vascular Surgery (SVS) system was calculated.11
Intraprocedural and postprocedural complications were
reviewed. Time to discharge and dischargemedications were
recorded. Follow-up clinic visits were reviewed for changes
in symptoms, the pulse examination, or the ABI. A surveil-
lance ultrasound was recommended at 1 month, then every
3months for theﬁrst year, then yearly.However, compliance
with follow-up and participation in the surveillance ultra-
sound program was variable. The clinical presentation andindication prompting reintervention was noted, as were the
degrees of ischemia by the Rutherford classiﬁcation system.
The clinical end points under study were the composite
end point of any ipsilateral reintervention, loss of patency
without reintervention, stenosis, or major amputation (the
composite outcome of reintervention, amputation, or
stenosis [RAS]).13 This included any catheter-directed or
open reintervention other than below-ankle amputations.
Patency was deﬁned as absence of occlusion or a ﬂow-
limiting stenosis, deﬁned as a peak systolic velocity >300
cm/s by duplex ultrasound or an 80% stenosis by angiog-
raphy. Thrombolysis was deﬁned as any catheter-directed
thrombolysis or open thrombectomy of the treated limb as
a result of stent thrombosis.Major amputationswere deﬁned
as any amputation above the ankle level. A composite end
point of major adverse limb events (MALE) was deﬁned as
anymajor amputation, bypass procedure, or need for throm-
bolysis. Acute limb ischemia (ALI)was deﬁned as any sudden
loss of perfusion threatening viability of the limb (Rutherford
ALI classiﬁcation).11 Mortality was assessed using the Social
Security Death Index.
Statistical analysis was performed using STATA 12.1
(StataCorp LP, College Station, Tex). Interval variables
were analyzed using a one-way analysis of variance. Nominal
variables were analyzed with a Pearson c2 test unless the
number of observations mandated using a Fisher exact test.
Nonparametric analysis of ordinal variables was performed
using Wilcoxon rank-sum test. Logistic regression was
used for dichotomous outcome data to test predictors for
events. Survival analysis was performed for all time-to-event
data. Cox proportional hazards regression was used to test
predictors for clinical events. Predictors on univariate anal-
ysis that were found to be signiﬁcant (P< .10) were included
in a stepwise Cox regressionmodel with reverse selection for
signiﬁcant predictors. Univariate variables individually
examined included type of stent, sex, age >75, diabetes,
chronic renal insufﬁciency, end-stage renal disease
(ESRD), smoking status, statin use, claudication vs CLI,
TASC classiﬁcation, runoff score, presence of CTO, heavily
calciﬁed lesions, device diameter, number of stents per
limb, dual antiplatelet therapy, and surveillance ultrasonog-
raphy. Observations of clinical end points were assumed to
be independent despite having 17 patients with bilateral
interventions. All end points were re-evaluated with exclu-
sion of nonindependent observations, and no signiﬁcant
differences were noted in the outcomes.
RESULTS
Patient demographics and comorbidities. One
hundred thirty-four limbs in 100 patients met the inclu-
sion and exclusion criteriad71 were treated with BMS and
63 with SG. Patient demographics were similar between
groups; however, differences between the average age
(BMS, 72.0 6 12.1 vs SG, 68.5 6 10.7; P ¼ .08) and the
presence of ESRD (BMS 12 vs SG 4; P ¼ .06) approached
signiﬁcance. The remainder of the patient demographics,
medical comorbidities, medication use, and smoking status
were similar between groups (Table I).
Table I. Patient demographics, comorbid conditions
and indications in patients undergoing percutaneous
lower extremity revascularization
BMS % SG % P
Number of limbs treated 71 53 63 47
Mean age (SD) 72.0 12.1 68.5 10.7 .08
Female sex 24 34 16 25 .29
Comorbid conditions
CAD 29 41 24 38 .75
Previous MI 12 17 10 16 .87
CHF 5 7 2 3 .45
CVA 1 1 4 6 .19
HTN 54 76 51 81 .49
DM 29 41 26 41 .96
CRI 13 18 9 14 .53
ESRD 12 17 4 6 .06
Hyperlipidemia 44 62 40 63 .86
COPD 5 7 5 8 .57
Home O2 1 1 1 2
Immunosuppression 3 4 0 0 .25
Smoking status .36
Never 11 15 6 10
Former 44 62 37 59
Current 16 23 20 32
Indication for intervention
Rutherford class <.05
Class 2 2 3 0 0
Class 3 32 45 42 67
Class 4 9 13 7 11
Class 5 9 13 8 13
Class 6 19 27 6 10
Total claudicants 34 48 42 67
Total CLI 37 52 21 33
BMS, Bare metal stent; CAD, coronary artery disease; CLI, chronic limb
ischemia; CHF, congestive heart failure; COPD, chronic obstructive
pulmonary disease; CRI, chronic renal insufﬁciency (GFR <60); CVA,
cerebrovascular accident; DM, diabetes mellitus; ESRD, end-stage renal
disease; GFR, glomerular ﬁltration rate; HTN, hypertension; MI, myocar-
dial infarction; SD, standard deviation; SG, stent graft.
P values of <.05 are listed in bold.
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vention were different between the two cohorts
(Table I). Thirty-seven of 71 (52%) BMS patients pre-
sented with CLI (Rutherford class $4), whereas 24/63
(38%) of patients treated with SG had a manifestation of
CLI (P < .05). By TASC II classiﬁcation, the anatomy of
the lesions was similar between groups (TASC C or D 27/
70 BMS vs 35/63 SG; P ¼ .11). However, on subgroup
analysis of patients with claudication, a signiﬁcantly greater
number of TASC D lesions were treated with SG (4/34
BMS vs 17/42 SG; P < .01).
There were additional differences between the cohorts.
The distribution of runoff scores was signiﬁcantly worse in
the BMS group (P < .05) (Table II). In contrast, CTOs
were more common in the SG group (21/71 BMS vs
37/63 SG; P < .01). There was no difference in the
number of hybrid procedures between groups (12/70
BMS vs 10/63 SG; P ¼ NS). In eight limbs, the distal
extent of the BMS extended to the knee joint, whereas
no SG extended to that level (P < .01). Otherwise, the
minimum device size (#5 mm), the number of devicesimplanted per limb, and the degree of heavy calciﬁcation
(31/71 vs 26/63; P ¼ NS) were not different between
the device groups.
Procedural complications. Intraprocedural complica-
tions were infrequent. There was one embolization event in
theBMS group and three access-site complications in the SG
group (P ¼ NS). Postprocedural complications included
four patients with troponin leaks and four with contrast-
induced nephropathy in the BMS cohort, while in the SG
cohort, one patient developed renal failure requiring hemo-
dialysis and another developed a new cardiac arrhythmia.
Antithrombotic regimen and surveillance. The
majority of patients were discharged on acetylsalicylic acid
and Plavix (44/71 of BMS vs 50/63 of SG; P < .05)
(Table III). In our early experience, patients treated with
BMS were discharged on Plavix alone. In sum, 17/71
patients with BMSwere on Plavix alone in comparison to 4/
63 SG patients (P < .05). The median follow-up was 738
days (range, 27-1720) for the BMS cohort and 743 days
(range, 10-2229) for the SG cohort. Surveillance ultra-
sounds were available in 91/134 limbs. All patients were
followed with clinical examination, recording a change in
symptoms or a change in the ABIs.
RAS. Signiﬁcantly more patients treated with BMS
required RAS compared with those treated with SG.
Freedom from RAS at 1 year was 75% in the SG group and
64% in the BMS group (hazard ratio [HR], 0.46; 95% conﬁ-
dence interval [CI], 0.25-0.78; P < .01) (Fig 1). Reinter-
ventions were prompted by a change in symptoms or
a change in ABI in most, except in 15 patients where the
reintervention was prompted by ﬁndings on surveillance
ultrasound. Multivariable predictors of RAS (Table IV)
included the presence of a CTO (HR, 1.6; 95% CI, 1.1-
2.32) or ESRD (HR, 2.51; 95% CI, 1.46-4.31). Factors
protective against RAS included a minimum stent diameter
of $6 mm (HR, 0.66; 95% CI, 0.44-0.99). A BMS was
protective over an SG in the multivariable analysis (HR,
0.68; 95%CI, 0.47-1.01; P¼ .06), however, it did not reach
the threshold for signiﬁcance. On subgroup analysis of
claudicants, the only predictor for reintervention on multi-
variable analysis was a device diameter of$6mm (HR, 0.32;
95% CI, 0.16-0.62).
MALE. There were 13 patients in the BMS cohort who
were subsequently treated with an SG during follow-up.
MALE and occurrence of ALI were assigned by the last
treatment received. Events were also analyzed according to
the ﬁrst treatment received, with no major changes in our
conclusions. Including the cross-over limbs by their ﬁnal
cohort assignment, there were 14MALE events in the BMS
group and17 in the SGgroup.Overall, freedom fromMALE
was no different between groups (HR, 0.73; 95% CI, 0.36-
1.50) (Fig 2). However, the distribution of MALE event
subgroup types was signiﬁcantly different (Table V). There
were 2/58 patients who required thrombolysis in the BMS
group in comparison to 11/76 patients in the SGgroup (P<
.05). There were no bleeding complications related to
thrombolysis. On multivariable analysis, the only signiﬁcant
predictors of need for thrombolysis were BMS vs SG
Table II. Patient anatomy and procedural characteristics of patients treated with either BMS or SG
BMS % SG % P
Overall TASC II classiﬁcation
A 9 13 16 25 .11
B 34 49 12 19
C 17 24 8 13
D 10 14 27 43
Claudicant subgroup TASC II classiﬁcation
A 5 15 12 29 <.01
B 20 61 8 19
C 4 12 5 12
D 4 12 17 40
Runoff score
0 8 11 16 25 <.05
1 28 40 24 38
2 22 31 19 30
3 12 17 4 6
CTO 21 30 37 59 <.01
Heavy calciﬁcation 31 44 26 41 .79
Extent of SFA coverage <.05
Proximal SFA 25 33
Mid-SFA 49 46
Distal SFA 52 56
Popliteal 8 0
Minimum device size
#5 mm 13 18 12 19
$6 mm 58 82 51 81
Number of devices per limb (index case only) .06
1 36 51 21 33
2 22 31 18 29
$3 13 18 24 38
BMS, Bare metal stent; CTO, chronic total occlusion; SFA, superﬁcial femoral artery; SG, stent graft; TASC, TransAtlantic Inter-Society Consensus.
P values of <.05 are listed in bold.
Table III. Antithrombotic regimens postprocedure and
median follow-up for both cohorts
BMS % SG %
Postprocedure medications
ASA þ Plavix 44 62 50 79
ASA þ Coumadin 4 6 3 5
Plavix þ Coumadin 2 3 1 2
ASA 3 4 3 5
Plavix 17 24 4 6
Coumadin 1 1 1 2
Follow-up, days
Median 738 743
SD 541 522
ASA, Acetylsalicylic acid; BMS, bare metal stent; SD, standard deviation;
SG, stent graft.
Fig 1. Freedom from reintervention, amputation, or stenosis
(RAS) survival estimates, stratiﬁed by type of stent used. The
vertical reference line is set at 1 year. A Cox proportional hazard
regression (hazard ratio [HR], 0.46; 95% conﬁdence interval [CI],
0.25-0.78) demonstrates the difference between the two cohorts.
BMS, Bare metal stent; SG, stent graft.
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1.48; 95% CI, 1.03-2.11). There were four major amputa-
tions in the BMS group in comparison to no amputations in
the SG group. The time tomajor amputationwas 35, 77, 98,
and 115 days. Over the course of the follow-up period, there
were 33 deaths. There were no deaths within 30 days of the
index procedure.
ALI. A clinical presentation of ALI during follow-up
was observed only within the SG-treated patients (nine vs
zero, log-rank P < .02) (Fig 3). Five patients presentedwith Rutherford class IIa ischemia and one with a Ruth-
erford class IIb ischemia. In ﬁve of these nine patients, the
indication for the initial intervention was claudication. The
preprocedure TASC classiﬁcation included three patients
Table IV. Multivariable analysis of predictors for major
clinical events
HR 95% CI P
Any reintervention
BMS vs SG 0.68 0.47-1.01 .058
CTO 1.6 1.10-2.32 <.05
ESRD 2.51 1.46-4.31 <.01
Diameter $6 mm 0.66 0.44-0.99 <.05
MALE
ESRD 3.43 1.99-5.94 <.01
Thrombolysis
BMS vs SG 0.53 0.37-0.76 <.01
CTO 1.48 1.03-2.11 <.05
ALI
BMS vs SG 0.52 0.36-0.75 <.01
CTO 1.44 1.00-2.06 <.05
ALI, Acute limb ischemia; BMS, bare metal stent; CI, conﬁdence interval;
CTO, chronic total occlusion; ESRD, end-stage renal disease; HR, hazard
ratio; MALE, major adverse limb event; SG, stent graft.
A stepwise Cox regression with backward selection for variables identiﬁed
on univariate analysis was used to construct the models. Only signiﬁcant
ﬁndings are included.
Table V. A summary of major late clinical events in both
cohorts
BMS % SG % P
Any reintervention 41 58 22 35 <.01
Number of crossovers 13 0
MALE 14 24 17 22 .71
Bypass 9 16 14 18
Thrombolysis 2 3 11 14
Major amputation 4 7 0 0
ALI 0 9 12 <.05
Stage I 3 4
Stage IIa 5 7
Stage IIb 1 1
Net change in Rutherford class
Claudicants progressing to CLI 5 13 4 7 .27
Claudicants progressing to
CLI þ ALI
5 13 13 17 .15
ALI, Acute limb ischemia; BMS, bare metal stent; CLI, chronic limb
ischemia; MALE, major adverse limb event; SG, stent graft.
P values of <.05 are listed in bold.
Fig 2. Survival estimates for freedom from major adverse limb
events (MALE). The difference between estimates is not signiﬁ-
cant. BMS, Bare metal stent; CI, conﬁdence interval; HR, hazard
ratio; SG, stent graft.
Fig 3. Survival estimates for freedom from acute limb ischemia
(ALI). There were no ALI events in the bare metal stent (BMS)
group. SG, Stent graft.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Vartanian et al 1529with TASC A lesions. On multivariable analysis, predictors
for ALI included the type of stent used (BMS vs SG; HR,
0.52; 95% CI, 0.36-0.75) and presence of a CTO (HR,
1.44; 95% CI, 1.0-2.1). Four patients required a bypass
operation, two required thrombolysis followed by a bypass,
and three were salvaged with thrombolysis followed by
repeat stenting. Four of the nine patients with ALI had
lost runoff because of thrombus in the infrageniculate
vessels. Two of the four were salvaged with thrombolysis
(Table VI).
Clinical deterioration. On subgroup analysis of
patients whose initial indication for intervention was claudi-
cation, 5/34 (9%) limbs treated with BMS progressed to
CLI during follow-up. In comparison, 13/42 (17%)limbs in the SG cohort progressed from claudication to
either CLI or ALI when the SG failed (P ¼ .16).
DISCUSSION
The purpose of this study was to investigate differences
in the frequency andmagnitude of late adverse clinical events
in patients with FPOD treated with self-expanding nitinol
stents or with SG and to identify risk factors for those events.
A number of important differences in outcomes between the
groups were observed, however, these ﬁndings must be
interpreted with an understanding of important limitations
of our study design.
Despite our best effort to study similar cohorts of
patients, there were a number of key differences between
groups that could help account for our observations. We
limited our study to patients who underwent percutaneous
Table VI. A summary of ALI events, including
indication for intervention, lesion anatomy by TASC II
classiﬁcation, and the clinical outcome of the limb
ALI event
number
Preprocedure
Rutherford
classiﬁcation TASC II
Loss of
runoff Outcome
1 3 D Yes Bypass
2 5 D No Thrombolysis with
repeat stenting
3 3 C Yes Thrombolysis with
bypass and
fasciotomy
4 4 D Yes Bypass
5 6 A No Thrombolysis with
repeat stenting
6 4 A No Bypass
7 3 A No Bypass
8 3 D No Thrombolysis with
repeat stenting
9 3 D Yes Thrombolysis with
bypass
ALI, Acute limb ischemia; TASC, TransAtlantic Inter-Society Consensus.
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occlusive disease. This excluded patients with previous treat-
ment failures and minimized the selection bias by studying
patients who had been deemed a good ﬁt for endovascular
interventions. Overall, the demographics and comorbid
conditions were similar, but key differences in indication
and anatomy were present. Signiﬁcantly more claudicants
were treated with SG than BMS. Although overall the
anatomic pattern of disease between the two groups was
similar, subgroup analysis of claudicants showed more
TASC D lesions were treated with SG than BMS (40% vs
12%). Other differences such as runoff status, percentage
of limbs with CTOs, and the location of the stents also
differed. These differences limit the ability to make direct
comparisons between groups, but also likely represent
“real-world” application of the competing technologies,
and hence, the results are noteworthy.
Overall, the 1-year freedom from reintervention rate
for SG was 75%. Our 1-year results were similar to most
other reports regarding SG in FPOD. Of the larger
randomized trials using SG in the SFA, Kedora et al
showed a 1-year primary patency rate of 72% in a prospec-
tive trial comparing SG against a prosthetic surgical
bypass.9 Saxon et al had observed a primary patency rate
of 65%.8 The VIBRANT trial has reported interim results,
but the primary end point of 3-year follow-up has not yet
been published. In their presentation, 1-year primary
patency was 53%. It should be noted that unlike in those
trials, all the limbs in our study were treated with
a heparin-bonded device. Whether the heparin-bonded
surface confers an additional clinical advantage is unknown.
The reintervention rate was signiﬁcantly higher for
BMS at 1 year. Well-known risks for reintervention
following stent placement for FPOD include vessel diam-
eter, length of lesion treated, and runoff status.14-16 The
results presented here echo these ﬁndings, and onmultivariable analysis, stent diameter of <6 mm and treat-
ing CTOs were predictors for reintervention. In addition,
ESRD and treating with BMS vs SG were also predictors
for needing reintervention. Whether this is related to
patterns of diffuse in-stent stenosis seen in BMS as opposed
to edge stenosis seen in SG is speculated but unknown.
Our most salient ﬁnding relates to the severity of
ischemia following failure of these interventions. Claudi-
cants treated with either technology did not necessarily
revert back to claudication when the percutaneous treat-
ment failed. Of the 34 claudicant limbs treated with
BMS, ﬁve (9%) subsequently presented with CLI, whereas
of the 42 limbs treated with SG, 13 (17%) subsequently
presented with either CLI or ALI. Although these ﬁndings
were not statistically signiﬁcant (P ¼ .16), the absolute
difference of 9% vs 17% suggests that a study examining
larger numbers of patients or longer follow-up periods
may prove the difference to be real.
We also observed that a signiﬁcant number of patients
treated with SG developed ALI following SG thrombosis.
We did not observe ALI in the BMS group. These events
occurred evenly in patients with initial presentations of
CLI or claudication, and surprisingly, they occurred in three
out of nine patients who had TASC A lesions. In sum, 12%
of the total SG cohort ultimately presented with ALI at
a later time. The only predictor for ALI on multivariable
analysis was SG use and the presence of a CTO. In the
Viabahn Endoprosthesis vs Bare Nitinol Stent study
(VIBRANT) trial, which is a prospective study of claudi-
cants, 1-year data presented in abstract form notes that
9/72 (13%) claudicants treated with SG developed subse-
quent CLI or ALI, in comparison to 6/76 (8%) patients
treated with BMS that had progression of their claudication
on device failure.We await publication of these study results.
The composite end point of MALE was not different
between the groups; however, the types of MALE events
were different. Freedom from MALE was no different in
large part because of the number of major amputations in
the BMS group (n ¼ 4), whereas there was no amputation
in the SG cohort. As all the major amputations were in
patients with Rutherford class VI ischemia, and the time
to amputation for all events was within 4 months of the
BMS placement, it can be argued that primary amputation
should have been considered rather than aggressive limb
salvage in these cases.
Conversely, thrombolysis was far more prevalent in SG
failure.Our grouphas previously shown ahigh rate of throm-
bolysis for limbs treated with SG, and although the patients
in this cohort are different than the patients in that study, we
found similar results in this group as well.17 It should be
noted that in most cases, thrombolysis was used to
re-establish patency within the SG, rather than to salvage
lost runoff, although four patients did have distal emboliza-
tion related to SG thrombosis with subsequent loss of runoff.
The timing of the embolization is uncertain, and we cannot
exclude the possibility that embolization occurred either
while crossing the thrombosed SG or during the thrombol-
ysis process.
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a differing group of patients. Johnson et al noted similar rates
of reintervetion, MALE, and ALI in all patients with FPOD
treated with SG. There are signiﬁcant differences between
the cohort of patients in that report and this series. In this
study, only patients undergoing their index procedure for
FPOD were included, whereas in Johnson et al, nearly
one-third of patients had a previous BMS that were relined
with an SG. This series is also more contemporary, including
only patients after 2007. This limited the effect of device
modiﬁcations on outcomes, including the addition of
a bioactive heparinzed surface. Multivariable analysis of risk
factors for reintervention and MALE were complementary,
although one difference was the effect of dual antiplatelet
therapy. In our series, this was not a risk factor for any of
the endpoints under study. Thismaybe a result of a sampling
error, as only 13% of the SG cohort was on a single agent.
Another limitation of this study is the lack of detailed
data about the cost of each intervention or reintervention.
The cost of the sum of the interventions coupled with
pretreatment levels of disability and functional outcomes
are important in determining the value of each treatment.
The rapid introduction of new and diverse technologies
for treating infrainguinal occlusive disease, and the paucity
of comparative effectiveness research comparing tech-
niques, makes choosing a single optimal treatment strategy
difﬁcult. The picture may become even more muddled
with the introduction of drug-eluting balloons and stents.
In conclusion, although the reintervention rate for
FPOD treated with SG may be lower, the clinical presenta-
tion of failed percutaneous treatment is different between
BMS and SG. SG failure is more likely to present with
advanced ischemia, including a 10% rate of ALI. In light of
the high risks associated with failure, patients should be care-
fully selected for percutaneous interventions, particularly
claudicants with TASC D lesions. SG should not be used
indiscriminately in claudicants with FPOD, as the risks asso-
ciated with treatment failure may be worse than the natural
history of untreated disease.
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